The latest development comes after the US Food and Drug Administration cleared the company’s investigational new drug application for TST005. Credit: Ed Uthman.

Transcenta is set to begin the Phase I clinical trial of its bi-functional anti-PD-L1/TGF-β antibody, TST005, for treating various tumour types.

The latest development comes after the US Food and Drug Administration cleared its investigational new drug application for TST005.

A bi-functional anti-PD-L1 and TGF-β trap fusion protein, TST005 can concurrently target two immuno-suppressive pathways used by cancer cells for attacking the immune system.

Transcenta executive vice-president, Global R&D head and CMO Dr Michael Shi said: “TST005 is one of the few leading PD-L1/TGF-β bi-functional antibody drug candidates currently in clinical development globally.

“We plan to simultaneously develop TST005 both in China and the US under the same Phase I protocol with an innovative basket trial design.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

“With the IND Clearance for TST005 in the US, we will accelerate the clinical development globally by allowing Chinese patients dosed at the current dose level when joining the study upon Chinese IND clearance.”

In vitro, TST005 demonstrated potential activity in reversing TGF-β induced T-cell suppression.

The drug prompted a significant rise in CD8 T-cell infiltration into PD-L1 expressing tumours in various syngeneic models and showed dose-dependent growth inhibition in tumour model with increased TGF-β level.

Furthermore, TST005 was well tolerated in non-human primates and had a linear pharmacokinetic profile.

Separately, Transcenta has enrolled and dosed the first subject in Phase I clinical study of TST001, a humanised monoclonal antibody plus CAPOX for treating patients with first-line locally advanced unresectable or metastatic gastric cancer.

This antibody demonstrated more potent anti-tumour activities than IMAB362 analogue in mouse xenograft experiments.

Shi added: “We hope to explore the safety, tolerability and anti-tumour activity of TST001 combined with CAPOX in first-line gastric cancer patients through this study, so as to provide a basis for later registrational clinical studies.”